LACQ Leisure Acquisition Corp.

Subscribe to $LACQ

Leisure Acquisition Corp.

Subscribe to $LACQ

$LACQ

Business Services

Finance

IPO Year: 2017

Exchange: NASDAQ

Recent Analyst Ratings for Leisure Acquisition Corp.

Date	Price Target	Rating	Analyst

See more ratings

Leisure Acquisition Corp. Press Releases

Fastest customizable press release news feed in the world

MRC Global Announces Agreement with Engine Capital and Appointment of Daniel Silvers to the Board of Directors
HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- MRC Global Inc. (NYSE:MRC) ("MRC Global" or the "Company"), the leading global distributor of pipe, valves and fittings (PVF) and other infrastructure products and services to diversified gas utility, energy and industrial end-markets, today announced that Daniel Silvers has been appointed to the Company's Board of Directors, effective immediately. Mr. Silvers will serve on the Board's Compensation and Environmental, Social, Governance and Enterprise Risk Committees. Mr. Silvers' appointment is made in conjunction with a cooperation agreement that the Company has reached with Engine Capital, L.P. ("Engine"). Robert Wood, MRC Global'
4/2/24 6:30:18 AM ET
$INSE
$MRC
$LACQ
Computer Software: Prepackaged Software
Technology
Industrial Machinery/Components
Industrials
Engine Nominates Two Highly Qualified Candidates for Election to MRC Global's Board of Directors at the 2024 Annual Meeting
Believes it is Critical to Add Directors with an Investor Mindset, and Capital Allocation and Financial Markets Experience Underscores Engine's Repeated Attempts to Avoid an Election Contest, Including by its Willingness to Settle for Reduced Board Representation Engine Capital, L.P. (together with its affiliates, "Engine"), a significant shareholder of MRC Global Inc. (NYSE:MRC) ("MRC" or the "Company") and the owner of nearly 4.3% of the Company's outstanding common stock, today announced it has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with its nomination of two highly qualified candidates for election to the Company's Board of
3/19/24 9:00:00 AM ET
$AOUT
$AVID
$INSE
$MRC
Recreational Games/Products/Toys
Consumer Discretionary
Computer Software: Prepackaged Software
Technology
Ensysce Biosciences to Commence Trading on the OTC on July 1, 2021
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (OTC:LACQ, LACQW))) today announced that, in connection with the closing of its previously announced merger with Leisure Acquisition Corp. ("LACQ"), the combined company, Ensysce Biosciences, Inc., will commence trading its common stock and warrants under the ticker symbols "LACQ" and "LACQW," respectively, on the OTC Market on July 1, 2021. As previously announced, the merger was approved by LACQ's shareholders on June 28, 2021 and closed on June 30, 2021. The Company will announce further trading information at a later time. Forward Looking Statements This press release contains certain
6/30/21 8:32:54 PM ET
$LACQ
Business Services
Finance
Leisure Acquisition Corp. Announces Receipt of and Plan to Appeal Nasdaq Listing Determination
NEW YORK, June 1, 2021 /PRNewswire/ -- Leisure Acquisition Corp. ("LACQ" or the "Company") (NASDAQ:LACQ, LACQU, LACQW))), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that on June 1, 2021, Nasdaq notified LACQ that trading in the Company's securities on Nasdaq will be suspended effective with the open of the market on Thursday, June 3, 2021 due to the Company's failure to complete an initial business combination by June 1, 2021, which date the notice stated represented the full extent of the Nasdaq Hearing Panel's discretion in this matter. The Company expects that its securities will be immed
6/1/21 5:15:00 PM ET
$LACQ
Business Services
Finance
Ensysce Biosciences' Covistat Subsidiary "At Home Coronavirus Pill" Commencing to Phase 2 clinical development
NEW YORK and SAN DIEGO, May 07, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce"), which has entered into an agreement for a business combination with Leisure Acquisition Corp. ("LACQ") (NASDAQ:LACQ, LACQU, LACQW))), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that Ensysce's subsidiary, Covistat, will be presenting at the upcoming American Thoracic Society (ATS) Annual Meeting to be held May 14-19, 2021. ATS 2021 showcases the latest advances and discoveries in respiratory science, patient care and global respiratory health. Covistat will present a summary of its findings th
5/7/21 8:00:00 AM ET
$LACQ
Business Services
Finance
Ensysce Biosciences Receives Investigational New Drug Allowance for its Unique PF614-MPAR™ Opioid with Overdose Protection
NEW YORK and SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce") and Leisure Acquisition Corp. ("LACQ") (NASDAQ:LACQ, LACQU, LACQW))), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that Ensysce has received U.S. Food and Drug Administration ("FDA") allowance for an Investigational New Drug (IND) application for PF614-MPAR™, a two-step extended-release oxycodone prodrug which is designed to provide abuse deterrent and overdose protection properties. PF614-MPAR™ is designed as an extended-release oxycodone prodrug with both trypsin-activated abuse protection (TA
4/29/21 8:00:00 AM ET
$LACQ
Business Services
Finance
Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences
GAINESVILLE, Ga., April 15, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of additional agreements with an existing customer, Ensysce Biosciences, Inc. ("Ensysce"). Under these new agreements, Recro will provide early-stage development and manufacturing services to support two of Ensysce's development programs. Recro and Ensysce have already commenced the initial phase of these projects. "We are delighted that Ensysce has elected to expand our relationshi
4/15/21 7:00:00 AM ET
$REPH
$LACQ
Biotechnology: Pharmaceutical Preparations
Health Care
Business Services
Finance
Ensysce Biosciences, Inc. And Leisure Acquisition Corp. Announce Appointment Of Dave Humphrey As Chief Financial Officer
NEW YORK and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Ensysce Biosciences Inc. ("Ensysce"), a clinical stage pharmaceutical company developing medicines for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, and Leisure Acquisition Corp. (NASDAQ: LACQ) ("LACQ") today announced the appointment of David Humphrey to Ensysce's management team as its Chief Financial Officer. Mr. Humphrey brings over 20 years of experience with development-stage companies as they progress toward product commercialization. Prior to joining Ensysce, Mr. Humphrey was Chief Financial Officer of Senomyx, Inc., a publicly-held biotechnology company which he led through an acquisition by F
2/18/21 7:30:00 AM ET
$LACQ
Business Services
Finance
Ensysce Biosciences, Inc. And Leisure Acquisition Corp. To Host Investor Call Regarding Business Combination On February 3, 2021
NEW YORK and SAN DIEGO, Feb. 2, 2021 /PRNewswire/ -- Leisure Acquisition Corp. (NASDAQ: LACQ, LACQU, LACQW) ("Leisure"), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, and Ensysce Biosciences, Inc. (together with its affiliated entities, "Ensysce" or the "Company"), jointly announced today that Leisure and Ensysce will host an investor conference call on February 3, 2021 to discuss their previously announced business combination (the "Transaction") whereby Ensysce will merge into a wholly-owned subsidiary of Leisure in a transaction that reflects a pro forma enterprise valuation for Ensysce of approximately
2/2/21 4:15:00 PM ET
$LACQ
Business Services
Finance
Leisure Acquisition Corp. Enters Into Merger Agreement For Business Combination With Ensysce Biosciences, Inc.
NEW YORK and SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Leisure Acquisition Corp. ("Leisure") (NASDAQ: LACQ, LACQU, LACQW), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that it has entered into a definitive agreement to acquire Ensysce Biosciences, Inc. (together with its affiliated entities, "Ensysce" or the "Company"). The transaction reflects an enterprise valuation for Ensysce of $207 million, including the Company's existing convertible indebtedness, but excluding transaction expenses as well as the impact of Leisure's sponsor shares and subject to certain closing adjustments. Consid
2/1/21 8:00:00 AM ET
$LACQ
Business Services
Finance

Leisure Acquisition Corp.

Recent Analyst Ratings for Leisure Acquisition Corp.

Leisure Acquisition Corp.

Recent Analyst Ratings for Leisure Acquisition Corp.

Leisure Acquisition Corp. Leadership Updates

Live Leadership Updates

MRC Global Announces Agreement with Engine Capital and Appointment of Daniel Silvers to the Board of Directors

Leisure Acquisition Corp. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Chang William H was granted 2,595,640 units of Common Stock

SEC Form 4: Humphrey David Carl was granted 50,000 units of Common Stock

SEC Form 4: GOWER BOB G was granted 7,919,026 units of Common Stock

SEC Form 4 filed by Martin Steven Robert

SEC Form 4 filed by Benton Andrew

SEC Form 4: Kirkpatrick Lynn was granted 284,851 units of Common Stock

SEC Form 4 filed by Wright Richard Chester

SEC Form 4 filed by Birkett Kevin Geoffrey

SEC Form 4 filed by Schmidt William K

SEC Form 3 filed by Kirkpatrick Lynn

Leisure Acquisition Corp. SEC Filings

Leisure Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Leisure Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Leisure Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Leisure Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form EFFECT filed by Leisure Acquisition Corp.

SEC Form 424B3 filed by Leisure Acquisition Corp.

SEC Form S-4/A filed by Leisure Acquisition Corp. (Amendment)

SEC Form 425 filed by Leisure Acquisition Corp.

Leisure Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

Leisure Acquisition Corp. Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Leisure Acquisition Corp. (Amendment)

SEC Form SC 13D filed by Leisure Acquisition Corp.

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

SEC Form SC 13G filed

SEC Form SC 13G filed

Leisure Acquisition Corp. Press Releases

Fastest customizable press release news feed in the world

MRC Global Announces Agreement with Engine Capital and Appointment of Daniel Silvers to the Board of Directors

Engine Nominates Two Highly Qualified Candidates for Election to MRC Global's Board of Directors at the 2024 Annual Meeting

Ensysce Biosciences to Commence Trading on the OTC on July 1, 2021

Leisure Acquisition Corp. Announces Receipt of and Plan to Appeal Nasdaq Listing Determination

Ensysce Biosciences' Covistat Subsidiary "At Home Coronavirus Pill" Commencing to Phase 2 clinical development

Ensysce Biosciences Receives Investigational New Drug Allowance for its Unique PF614-MPAR™ Opioid with Overdose Protection

Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences

Ensysce Biosciences, Inc. And Leisure Acquisition Corp. Announce Appointment Of Dave Humphrey As Chief Financial Officer

Ensysce Biosciences, Inc. And Leisure Acquisition Corp. To Host Investor Call Regarding Business Combination On February 3, 2021

Leisure Acquisition Corp. Enters Into Merger Agreement For Business Combination With Ensysce Biosciences, Inc.